These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8172802)

  • 41. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
    Fumoleau P; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier MJ; Luporsi E;
    Ann Oncol; 2006 Jan; 17(1):85-92. PubMed ID: 16251204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
    Bonneterre J; Roché H; Kerbrat P; Brémond A; Fumoleau P; Namer M; Goudier MJ; Schraub S; Fargeot P; Chapelle-Marcillac I
    J Clin Oncol; 2005 Apr; 23(12):2686-93. PubMed ID: 15837983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.
    Lelli G; Tononi A; Bacchetti P; Maver P; Corrado G; Garofalo F; De Santis P; Pannuti F
    J Chemother; 1989 Aug; 1(4):269-71. PubMed ID: 2809695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial.
    Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
    Acta Oncol; 1992; 31(2):231-6. PubMed ID: 1622639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
    Kolarić K; Tomek R
    Tumori; 1990 Oct; 76(5):472-5. PubMed ID: 2256193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
    Riccardi A; Pugliese P; Danova M; Brugnatelli S; Grasso D; Giordano M; Bernardo G; Giardina G; Fava S; Montanari G; Pedrotti C; Trotti G; Rinaldi E; Poli MA; Tinelli C
    Br J Cancer; 2001 Jul; 85(2):141-6. PubMed ID: 11461067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
    Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
    Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
    Jassem J; Pieńkowski T; Płuzańska A; Jelic S; Gorbunova V; Mrsic-Krmpotic Z; Berzins J; Nagykalnai T; Wigler N; Renard J; Munier S; Weil C;
    J Clin Oncol; 2001 Mar; 19(6):1707-15. PubMed ID: 11251000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cancer of the breast in young women: should chemotherapy be intensified?].
    Piccart MJ
    Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
    [No Abstract]   [Full Text] [Related]  

  • 50. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
    Trudeau ME
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):7-13. PubMed ID: 11396366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
    Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inflammatory breast cancer: results of antracycline-based neoadjuvant chemotherapy.
    Ozmen V; Cabioglu N; Igci A; Dagoglu T; Aydiner A; Kecer M; Bozfakioglu Y; Dinçer M; Bilir A; Topuz E
    Breast J; 2003; 9(2):79-85. PubMed ID: 12603379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy.
    Vargas-Roig LM; Gago FE; Tello O; Martin de Civetta MT; Ciocca DR
    Int J Cancer; 1999 Apr; 84(2):129-34. PubMed ID: 10096243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Epirubicin--results in breast cancer].
    Hartlapp JH
    Onkologie; 1986 Aug; 9 Suppl 1():3-7. PubMed ID: 3528968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).
    Wils J; Coombes RC; Marty M; Bliss J; Woods E
    Drugs; 1993; 45 Suppl 2():46-50; discussion 49-50. PubMed ID: 7693422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
    Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
    Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
    Chan S; Davidson N; Juozaityte E; Erdkamp F; Pluzanska A; Azarnia N; Lee LW
    Ann Oncol; 2004 Oct; 15(10):1527-34. PubMed ID: 15367414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
    Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
    Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.